Genetically engineered viruses capable of selectively targeting cancer cells while leaving healthy cells unharmed are gaining popularity as a promising oncolytic treatment. San Francisco-based biotech firm Jennerex debuted JX-594, a genetically engineered virus that can selectively target tumors and cancerous … Continue reading
